Thrombotest versus One-Stage Prothrombin-Time Determination

Publisher Website
Google Scholar
Abstract
PROLONGED anticoagulant therapy of thromboembolic disease with coumarin and related drugs has become increasingly common in recent years and has heightened awareness of the shortcomings of the Quick one-stage prothrombin-time method for controlling dosage of the drug. Development of the one-stage prothrombin-time procedure made long-term anticoagulation possible. However, it has been the experience here and elsewhere1 that a major or minor bleeding episode may develop in many patients on long-term therapy, occasionally while the prothrombin time is in the therapeutic range. This range for the one-stage method is generally taken to be a patient's value one and a half to . . .